1. WHO. Global tuberculosis report 2020. Geneva. 2020.
2. National Bureau of Statistics of China. China Statistical Yearbook 2020. Beijing: China Statistics Press; 2020.
3. WHO. WHO | The End TB Strategy [Internet]. WHO. World Health Organization; 2015. Available from: http://www.who.int/tb/strategy/en/
4. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009 May;33(5):956–73.
5. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 2):S221-247.
6. WHO. WHO consolidated guidelines on tuberculosis. Module 1, Module 1, [Internet]. 2020 [cited 2021 Mar 1]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554956/
7. He Y-J, Zhang H-R, Xin H-N, Gao L. Optimizing the application of tuberculin skin test HE. Chinese Journal of Antituberculosis, 2021, 43(03): 204–210.
8. Harris RC, Sumner T, Knight GM, Evans T, Cardenas V, Chen C, et al. Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study. Lancet Glob Health. 02 2019;7(2):e209–18.
9. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Dye C, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13980–5.
10. Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A, et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15520–5.
11. Dye C, Watt CJ, Bleed DM, Williams BG. What is the limit to case detection under the DOTS strategy for tuberculosis control? Tuberculosis (Edinb). 2003;83(1–3):35–43.
12. Ozcaglar C, Shabbeer A, Vandenberg SL, Yener B, Bennett KP. Epidemiological models of Mycobacterium tuberculosis complex infections. Math Biosci. 2012 Apr;236(2):77–96.
13. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 03 14, 2019;380(11):1001–11.
14. Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011 Jul 7;365(1):11–20.
15. Menzies D, Dion M-J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004 Aug 15;170(4):445–9.
16. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015 Aug 27;373(9):808–22.
17. Hermans SM, Grant AD, Chihota V, Lewis JJ, Vynnycky E, Churchyard GJ, et al. The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. BMC Med. 2016 Mar 23;14:45.
18. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011 Dec 8;365(23):2155–66.
19. Schein YL, Madebo T, Andersen HE, Arnesen TM, Dyrhol-Riise AM, Tveiten H, et al. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study. BMC Infect Dis. 2018 Nov 19;18(1):587.
20. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med. 08 02, 2018;379(5):440–53.
21. Soetaert K, Petzoldt T, Setzer RW. Solving Differential Equations in R: Package deSolve. Journal of Statistical Software. 2010;33(9):1–25.
22. Wang W-B, Zhang H, Petzold M, Zhao Q, Xu B, Zhao G-M. Cost-effectiveness of the Health X Project for tuberculosis control in China. Int J Tuberc Lung Dis. 2014 Aug;18(8):939–45.
23. 2010 Annual Conference on tuberculosis control. Progress of tuberculosis control in 2009. Beijing. 2010. p. 2–23. Available from: https://d.wanfangdata.com.cn/conference/ChZDb25mZXJlbmNlTmV3UzIwMjEwNTIxEgc3NDQ4ODYyGghwbTg2NWc1bg%3D%3D
24. The State Council. Circular of the general office of the State Council on Issuing the national TB control plan (2011-2015) [Internet]. [cited 2021 Jun 15]. Available from: http://www.gov.cn/zwgk/2011-12/06/content_2012869.htm
25. Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, et al. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med. 12 19, 2019;381(25):2429–39.
26. Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis. 2013 Oct;13(10):852–8.
27. Durovni B, Cavalcante S. Preventive therapy for HIV-associated tuberculosis. Curr Opin HIV AIDS. 11 2018;13(6):507–11.
28. Schrager LK, Vekemens J, Drager N, Lewinsohn DM, Olesen OF. The status of tuberculosis vaccine development. Lancet Infect Dis. 03 2020;20(3):e28–37.
29. Houben RMGJ, Menzies NA, Sumner T, Huynh GH, Arinaminpathy N, Goldhaber-Fiebert JD, et al. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. Lancet Glob Health. 11 2016;4(11):e806–15.
30. Harris RC, Sumner T, Knight GM, White RG. Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. Hum Vaccin Immunother. 11 2016;12(11):2813–32.